GlaxoSmithKline
NEWS
The newly-launched index takes a focused look at the breadth and depth of novel agents currently being developed within the most innovative pharmaceutical pipelines.
GlaxoSmithKline’s PARP inhibitor Zejula has been approved for wider use in some cancers.
It was another busy week for clinical trials. Here’s a look.
Biotech and pharma companies strengthen their leadership teams and boards of directors with this week’s appointments.
PARP inhibitors will be taking center stage at the European Society of Medical Oncology Congress as rival drugmakers aim to show off data that supports broader use of the drug in treating various cancers.
Research from the Wellcome Sanger Institute, GSK and Biogen, under the Open Targets initiative, has shown that thousands of differences in DNA between individuals, associated with immune diseases, are linked with the switching-on of a specific subtype of immune cells.
Immutep Limited announces that it will receive a milestone payment from GSK of GBP 4 million related to the the first patient being dosed in GSK’s Phase II clinical trial evaluating GSK2831781 in ulcerative colitis.
Immutep Limited announces that it will receive a milestone payment from GSK of £4 million related to the first patient being dosed in GSK’s Phase II clinical trial evaluating GSK2831781 in ulcerative colitis.
Companies from across the globe share updates on their business and pipelines.
JOBS
IN THE PRESS